Genovate Aims For Global Insulin Position Under $1bn Project

Genovate has begun construction of its first manufacturing facility for insulins as part of a total investment of $1bn and with the ambition to become China’s first, and the world's fourth largest, manufacturer of insulin using efficient and ecologically friendly production technology.

SHANGHAI - Groundbreaking of China’s first insulin ecological industrial park has taken place in the Changzhou National Hi-Tech district, in the hope of bringing to market the fifth generation of insulin products to compete with multinational pharmaceutical giants that now dominate the sector.

As a part of total $1bn investment, Genovate Biotechnology, backed by Changzhou Life and Heath Construction Development and the life...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia